Suppr超能文献

半胱氨酸蛋白酶组织蛋白酶在动脉粥样硬化性心血管疾病中的作用。

Cysteine Protease Cathepsins in Atherosclerotic Cardiovascular Diseases.

机构信息

Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University.

Department of Nephrology, Tongji Hospital, Tongji University.

出版信息

J Atheroscler Thromb. 2018 Feb 1;25(2):111-123. doi: 10.5551/jat.RV17016. Epub 2017 Oct 5.

Abstract

Atherosclerotic cardiovascular disease (ASCVD) is an inflammatory disease characterized by extensive arterial wall matrix protein degradation. Cysteine protease cathepsins play a pivotal role in extracellular matrix (ECM) remodeling and have been implicated in the development and progression of atherosclerosis-based cardiovascular diseases. An imbalance in expression between cathepsins (such as cathepsins S, K, L, C) and their inhibitor cystatin C may favor proteolysis of ECM in the pathogenesis of cardiovascular disease such as atherosclerosis, aneurysm formation, restenosis, and neovascularization. New insights into cathepsin functions have been made possible by the generation of knockout mice and by the application of specific inhibitors. Inflammatory cytokines regulate the expression and activities of cathepsins in cultured vascular cells and macrophages. In addition, evaluations of the possibility of cathepsins as a diagnostic tool revealed that the circulating levels of cathepsin S, K, and L, and their endogenous inhibitor cystatin C could be promising biomarkers in the diagnosis of coronary artery disease, aneurysm, adiposity, peripheral arterial disease, and coronary artery calcification. In this review, we summarize the available information regarding the mechanistic contributions of cathepsins to ASCVD.

摘要

动脉粥样硬化性心血管疾病(ASCVD)是一种炎症性疾病,其特征是广泛的动脉壁基质蛋白降解。半胱氨酸蛋白酶组织蛋白酶在细胞外基质(ECM)重塑中发挥关键作用,并与基于动脉粥样硬化的心血管疾病的发生和发展有关。组织蛋白酶(如组织蛋白酶 S、K、L、C)与其抑制剂胱抑素 C 之间的表达失衡可能有利于 ECM 的蛋白水解,从而导致心血管疾病如动脉粥样硬化、动脉瘤形成、再狭窄和新生血管形成。通过生成基因敲除小鼠和应用特异性抑制剂,对半胱氨酸蛋白酶的功能有了新的认识。炎症细胞因子调节培养的血管细胞和巨噬细胞中组织蛋白酶的表达和活性。此外,对组织蛋白酶作为诊断工具的可能性进行评估,结果表明组织蛋白酶 S、K 和 L 的循环水平及其内源性抑制剂胱抑素 C 可能是冠心病、动脉瘤、肥胖症、外周动脉疾病和冠状动脉钙化诊断的有前途的生物标志物。在这篇综述中,我们总结了有关组织蛋白酶对 ASCVD 的发病机制贡献的现有信息。

相似文献

1
Cysteine Protease Cathepsins in Atherosclerotic Cardiovascular Diseases.
J Atheroscler Thromb. 2018 Feb 1;25(2):111-123. doi: 10.5551/jat.RV17016. Epub 2017 Oct 5.
2
Cysteine protease cathepsins in atherosclerosis-based vascular disease and its complications.
Hypertension. 2011 Dec;58(6):978-86. doi: 10.1161/HYPERTENSIONAHA.111.180935. Epub 2011 Oct 10.
3
Cathepsin cysteine proteases in cardiovascular disease.
FASEB J. 2007 Oct;21(12):3029-41. doi: 10.1096/fj.06-7924com. Epub 2007 May 23.
4
Do cathepsins play a role in abdominal aortic aneurysm pathogenesis?
Ann N Y Acad Sci. 2006 Nov;1085:161-9. doi: 10.1196/annals.1383.028.
5
Cystatin C and cathepsins in cardiovascular disease.
Front Biosci. 2008 May 1;13:5780-6. doi: 10.2741/3115.
6
Cysteine protease cathepsins in cardiovascular disease: from basic research to clinical trials.
Nat Rev Cardiol. 2018 Jun;15(6):351-370. doi: 10.1038/s41569-018-0002-3.
7
Cathepsin B, K, and S are expressed in cerebral aneurysms and promote the progression of cerebral aneurysms.
Stroke. 2008 Sep;39(9):2603-10. doi: 10.1161/STROKEAHA.107.513648. Epub 2008 Jul 17.
8
Cysteinyl cathepsins: multifunctional enzymes in cardiovascular disease.
Chonnam Med J. 2012 Aug;48(2):77-85. doi: 10.4068/cmj.2012.48.2.77. Epub 2012 Aug 24.
9
Cysteinyl cathepsins in cardiovascular diseases.
Biochim Biophys Acta Proteins Proteom. 2020 Apr;1868(4):140360. doi: 10.1016/j.bbapap.2020.140360. Epub 2020 Jan 9.
10
Lysosomal cysteine proteases in atherosclerosis.
Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):1359-66. doi: 10.1161/01.ATV.0000134530.27208.41. Epub 2004 Jun 3.

引用本文的文献

3
Identification of Pivotal ceRNA Networks Associated with Stanford-A Aortic Dissection via Integrated Bioinformatics Analysis.
Int J Gen Med. 2025 Mar 17;18:1509-1527. doi: 10.2147/IJGM.S509177. eCollection 2025.
4
Vascular Extracellular Matrix in Atherosclerosis.
Int J Mol Sci. 2024 Nov 8;25(22):12017. doi: 10.3390/ijms252212017.
5
The role of integrin-related genes in atherosclerosis complicated by abdominal aortic aneurysm.
Medicine (Baltimore). 2024 Nov 15;103(46):e40293. doi: 10.1097/MD.0000000000040293.
6
Cathepsins and neurological diseases: a Mendelian randomization study.
Front Neurosci. 2024 Oct 3;18:1454369. doi: 10.3389/fnins.2024.1454369. eCollection 2024.
8
Plasma Proteomic Biomarkers in Alzheimer's Disease and Cardiovascular Disease: A Longitudinal Study.
Int J Mol Sci. 2024 Oct 6;25(19):10751. doi: 10.3390/ijms251910751.
9
Advances in Cathepsin S Inhibition: Challenges and Breakthroughs in Drug Development.
Pathophysiology. 2024 Sep 3;31(3):471-487. doi: 10.3390/pathophysiology31030035.
10
Relationship between cathepsins and cardiovascular diseases: a Mendelian randomized study.
Front Pharmacol. 2024 Jul 4;15:1370350. doi: 10.3389/fphar.2024.1370350. eCollection 2024.

本文引用的文献

1
Cathepsin K Deficiency Prevents the Aggravated Vascular Remodeling Response to Flow Cessation in ApoE-/- Mice.
PLoS One. 2016 Sep 16;11(9):e0162595. doi: 10.1371/journal.pone.0162595. eCollection 2016.
2
Cathepsin S Activity Controls Injury-Related Vascular Repair in Mice via the TLR2-Mediated p38MAPK and PI3K-Akt/p-HDAC6 Signaling Pathway.
Arterioscler Thromb Vasc Biol. 2016 Aug;36(8):1549-57. doi: 10.1161/ATVBAHA.115.307110. Epub 2016 Jun 30.
4
Selective cathepsin S inhibition attenuates atherosclerosis in apolipoprotein E-deficient mice with chronic renal disease.
Am J Pathol. 2015 Apr;185(4):1156-66. doi: 10.1016/j.ajpath.2014.11.026. Epub 2015 Feb 10.
5
Cathepsin S activity controls ischemia-induced neovascularization in mice.
Int J Cardiol. 2015 Mar 15;183:198-208. doi: 10.1016/j.ijcard.2015.01.058. Epub 2015 Jan 27.
6
Renin inhibition reduces atherosclerotic plaque neovessel formation and regresses advanced atherosclerotic plaques.
Atherosclerosis. 2014 Dec;237(2):739-47. doi: 10.1016/j.atherosclerosis.2014.10.098. Epub 2014 Oct 30.
7
Leukocyte cathepsin C deficiency attenuates atherosclerotic lesion progression by selective tuning of innate and adaptive immune responses.
Arterioscler Thromb Vasc Biol. 2015 Jan;35(1):79-86. doi: 10.1161/ATVBAHA.114.304292. Epub 2014 Nov 13.
8
Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm.
ACS Med Chem Lett. 2014 Aug 27;5(10):1138-42. doi: 10.1021/ml500283g. eCollection 2014 Oct 9.
9
Impact of circulating cathepsin K on the coronary calcification and the clinical outcome in chronic kidney disease patients.
Heart Vessels. 2016 Jan;31(1):6-14. doi: 10.1007/s00380-014-0570-z. Epub 2014 Aug 24.
10
Pharmacokinetics and pharmacodynamics of the cathepsin S inhibitor, LY3000328, in healthy subjects.
Br J Clin Pharmacol. 2014 Dec;78(6):1334-42. doi: 10.1111/bcp.12470.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验